Clinical Trials Logo

Adolescent Depression clinical trials

View clinical trials related to Adolescent Depression.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06325605 Completed - Clinical trials for Adolescent Depression

Efficacy and Safety of Bifidobacterium Combined With High-frequency Transcranial Magnetic Stimulation in the Treatment of Adolescent Depression

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

A total of 100 patients with adolescent depression who were admitted to our hospital between March 2022 and October 2022 were selected. On the basis of double blinding, these patients were randomly divided into the observation group(n=50) and the control group(n=50) using a random number table. 5S management method was used in the whole process of treatment to improve the hospital environment, increase the work efficiency and reduce the occurrence of cross infection through the effective implementation of the five steps of sort(Seiri), set in order(Seiton), shine (Seiso), standardize(Seiketsu) and sustain(Shitsuke).

NCT ID: NCT04603053 Completed - Anxiety Disorders Clinical Trials

Determining Effectiveness of an mHealth Intervention to Provide Adolescent CBT

Start date: November 9, 2020
Phase: N/A
Study type: Interventional

Washington University will evaluate the acceptability and effectiveness of a mobile health (mHealth) intervention to provide cognitive behavioral therapy for adolescents with depression.

NCT ID: NCT03154008 Completed - Depression Clinical Trials

Predictors of Response to Treatment for Depression

PORT
Start date: June 1, 2017
Phase: N/A
Study type: Interventional

The current study will examine neurophysiological, specifically event-related potential (ERP), measures of emotional processing as predictors of response to cognitive behavior therapy for adolescent depression.

NCT ID: NCT02017535 Completed - Clinical trials for Adolescent Depression

An Adaptive Treatment Strategy for Adolescent Depression-Continuation

PTAD GIA
Start date: June 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Aim 1: Assess the feasibility and acceptability of the personalized continuation treatment strategy. Aim 2: Estimate variances of primary and secondary outcomes with the continuation treatment. Aim 3: Conduct exploratory hypothesis-generating analyses to inform further development of the personalized continuation treatment strategy to be tested in a subsequent R01 proposal.

NCT ID: NCT01802437 Completed - Clinical trials for Adolescent Depression

An Adaptive Treatment Strategy for Adolescent Depression

PTAD
Start date: November 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is: 1. to find out how long teenagers getting talk therapy (interpersonal psychotherapy) for depression should get therapy before the therapist decides whether or not the teenager is improving enough, and 2. to compare two ways of providing treatment to teenagers who have not improved enough.

NCT ID: NCT00399776 Completed - Clinical trials for Adolescent Depression

Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy

Start date: October 2006
Phase: N/A
Study type: Observational

We hypothesize that antipsychotic induced hyperprolactinemia can decrease bone mineral accrual and decrease bone mineral content (BMC) in adolescents on antipsychotic therapy. Specifics Aims 1. To determine if antipsychotic therapy leads to decreased bone mineral accrual and decreased bone mineral content in a group of adolescents on antipsychotic therapy by comparing them to an ethnicity, gender and pubertal stage matched control group. 2. To determine the relationship between serum concentrations of prolactin, sex steroids and bone turnover markers in adolescents on antipsychotic therapy and an ethnicity, gender and pubertal stage matched control group.

NCT ID: NCT00312897 Completed - Clinical trials for Adolescent Depression

Omega-3 Fatty Acids in Adolescent Depression

Start date: December 2005
Phase: Phase 2
Study type: Interventional

Aim. To provide preliminary data about the efficacy of omega-3FA in the treatment of adolescent MDD. To address this aim, a 10-week double blind, placebo-controlled study of omega-3FA, using a flexible dose titration is proposed. Primary outcome measures will be: (1) change in the total score of the Children's Depression Rating Scale-Revised (CDRS-R) at the end of treatment (2) response rate on the Clinical Global Improvement scale (CGI) at the end of 10-week treatment. Hypothesis. Omega-3FA treatment in adolescents with MDD will result in a significant reduction of CDRS-R total scores, and a significantly higher improvement rate on the CGI at the end of treatment compared to placebo.